可溶性尿激酶纤溶酶原激活物受体与急性肾损伤
该研究在冠状动脉造影患者(3827例)、心脏手术患者(250例)和危重症患者(692例)中检测血浆suPAR水平,按四分位分析7天急性肾损伤(主要终点)和90天急性肾损伤或死亡(次要终点)风险。冠状动脉造影队列中8%(318例)发生急性肾损伤,suPAR最高四分位相比最低四分位的校正OR为2.66(95%CI 1.77-3.99),90天急性肾损伤或死亡校正OR为2.29(95%CI 1.71-3.06),外科和危重症队列结果相似。实验研究显示suPAR过表达小鼠给予造影剂后功能和组织学肾损伤更重,suPAR处理的人肾近端小管(HK-2)细胞能量需求增高和线粒体超氧化物生成增加,uPAR单克隆抗体预处理可减轻suPAR过表达小鼠肾损伤并使HK-2细胞生物能量学改变正常化。
要点
- 冠状动脉造影患者中suPAR最高四分位与最低四分位相比,7天急性肾损伤校正OR为2.66(95%CI 1.77-3.99)。
- 同一队列中suPAR最高四分位与最低四分位相比,90天急性肾损伤或死亡校正OR为2.29(95%CI 1.71-3.06)。
- 心脏手术和危重症队列中suPAR与急性肾损伤的关联与冠状动脉造影队列相似。
- suPAR过表达小鼠给予造影剂后功能和组织学急性肾损伤证据较野生型小鼠更重。
- uPAR单克隆抗体预处理可减轻suPAR过表达小鼠的肾损伤,并使HK-2细胞的生物能量学改变正常化。
适用人群与场景
- 接受冠状动脉造影的患者(3827例)。
- 接受心脏手术的患者(250例)。
- 入住重症监护室的危重症患者(692例)。
研究设计与关键结果
- 研究类型为临床队列联合实验研究,检测冠状动脉造影患者、心脏手术患者和危重症患者血浆suPAR水平,按四分位分析7天急性肾损伤(主要终点)和90天急性肾损伤或死亡(次要终点)。
- 冠状动脉造影队列3827例中318例(8%)发生急性肾损伤;suPAR最高四分位相比最低四分位,7天急性肾损伤校正OR为2.66(95%CI 1.77-3.99),90天急性肾损伤或死亡校正OR为2.29(95%CI 1.71-3.06)。
- 心脏手术队列(250例)和危重症队列(692例)中suPAR与急性肾损伤的关联与冠状动脉造影队列相似。
- suPAR过表达小鼠给予造影剂后功能和组织学急性肾损伤证据较野生型小鼠更重;suPAR处理的HK-2细胞能量需求增高和线粒体超氧化物生成增加;uPAR单克隆抗体预处理减轻suPAR过表达小鼠肾损伤并使HK-2细胞生物能量学改变正常化。
证据类型、等级与局限
- 证据类型:临床队列研究联合实验研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为高suPAR水平与多种临床和实验背景下的急性肾损伤相关。
- 实验研究提示uPAR单克隆抗体预处理可减轻suPAR过表达小鼠的肾损伤并正常化HK-2细胞的生物能量学改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. We investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and we used experimental models to identify mechanisms by which suPAR acts and to assess it as a therapeutic target.
METHODS: We measured plasma levels of suPAR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically ill patients. We assessed the risk of acute kidney injury at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. We also assessed cellular bioenergetics and generation of reactive oxygen species in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR.
RESULTS: The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells.
CONCLUSIONS: High suPAR levels were associated with acute kidney injury in various clinical and experimental contexts. (Funded by the National Institutes of Health and others.).
参考来源
- Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020. PMID: 31995687. doi:10.1056/NEJMoa1911481
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。